Spero Therapeutics, Inc.
Spero Therapeutics is a biopharmaceutical company developing treatments for MDR bacterial infections and rare diseases. Product candidates include tebipenem pivoxil HBr for urinary tract infections, SPR206 for Gram-negative pathogens, and SPR720 for non-tuberculous mycobacterial pulmonary disease. The company has license agreements with Meiji Seika Pharma, Everest Medicines, and Vertex Pharmaceuticals to support development and commercialization of these products.
Overview
Strengths
- Valued below its Biotechnology peers: P/E 6.7x vs. a median of 20.4x and EV/EBITDA 2.5x vs. a median of 15.6x.
- Consistent growth: revenue has compounded at 197.0% a year over 5 years, rising in 4 of them.
- Skin in the game: insiders own 23% of the shares, aligning management with shareholders.
- Cheaper than its own history: P/E 6.7x vs. a historical average of 69.1x and EV/EBITDA 2.5x vs. a historical average of 67.9x.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 15.2% in each of the last 6 years.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
- Our discounted cash flow target price (0.76 USD) is 25% below the current price.
- Unstable profitability: operating margin ranged from -30,664% to 28% over the last 6 years, with operating losses in 4 of them.
- Earnings quality red flag: reported profit exceeds operating cash flow by 30.8% of total assets.
- Earnings are projected to decline (-10.0% per year).
Key Financial Data